By open-sourcing its model, Boltz created a feedback loop where the community discovered novel use-cases, like a crude but effective "inference-time search" for antibody prediction. This demonstrates how open access allows external users to find creative applications the original developers hadn't considered.

Nonprofits occupy a unique space. While academia pursues discovery and industry seeks revenue, nonprofits can fund "infrastructure" projects like large, open-access datasets. These efforts accelerate the entire ecosystem, a goal neither academia nor industry is incentivized to pursue alone.

Open-source initiatives like OpenClaw can surpass well-funded corporate R&D because they leverage a global pool of contributors. This distributed approach uncovers genius in unlikely places, allowing for breakthroughs that siloed internal teams might miss.

Building the first large-scale biological datasets, like the Human Cell Atlas, is a decade-long, expensive slog. However, this foundational work creates tools and knowledge that enable subsequent, larger-scale projects to be completed exponentially faster and cheaper, proving a non-linear path to discovery.

Fears that universal tools reduce differentiation are misplaced. Instead of just leveling the playing field, open tools like OpenFold raise the entire industry's baseline capability. This shifts competition away from who builds the best foundational model to who can ask the most insightful scientific questions.

Regeneron's Genetics Center is a key competitive advantage, functioning as a discovery engine for new drug targets. By sequencing millions of patient genomes and linking them to health records, it allows Regeneron to identify novel genetic variants associated with diseases, feeding its antibody development pipeline with proprietary targets.

A biosecurity data-level (BDL) framework, modeled after biosafety levels for labs, would keep 99% of biological data open-access. Only the top 1% of data—that which links pathogen sequences to dangerous properties like transmissibility—would face restrictions like requiring use-approval.

Despite his many controversial views, James Watson was a staunch advocate for open science. He insisted his fully sequenced genome be published online for free research and actively argued against the National Institutes of Health's position that genes should be patented, believing they belonged to all humanity.

The true advantage of AI-driven science isn't superior creativity but a structural shift in collaboration. AI agents can share all raw data daily, creating a networked intelligence that learns exponentially faster than siloed human labs sharing polished results every few years.